CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


We found 6916 result(s)

Management of Neovascular Age-related Macular Degeneration: Systematic Drug Class Review and Economic Evaluation

Last Updated: February 24, 2009
Result type: Reports

In 2006, CADTH commissioned a study of the clinical efficacy and cost-effectiveness of drugs and therapies approved for use in Canada for people with neovascular age-related macular degeneration (AMD). You can view reported findings examining the impact of the pharmaceutical management of AMD in the report below. Report This complete report ha...